Evidence map›Paper›PMID 32844999›Full record

ArticleBlood2020

miR-125a-5p regulates megakaryocyte proplatelet formation via the actin-bundling protein L-plastin.

Seema Bhatlekar, Bhanu K Manne, Indranil Basak, Leonard C Edelstein, Emilia Tugolukova, Michelle L Stoller, Mark J Cody, Sharon C Morley, Srikanth Nagalla, Andrew S Weyrich and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. miR-146a mimic therapy protects against platelet-mediated thrombosis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. MicroRNA in adenoid cystic carcinoma (Review).International journal of oncology · 2023
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Seema BhatlekarProgram in Molecular Medicine, University of Utah, Salt Lake City, UT.
Bhanu K ManneProgram in Molecular Medicine, University of Utah, Salt Lake City, UT.
Indranil BasakProgram in Molecular Medicine, University of Utah, Salt Lake City, UT.
Leonard C EdelsteinCardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA.
Emilia TugolukovaProgram in Molecular Medicine, University of Utah, Salt Lake City, UT.
Michelle L StollerProgram in Molecular Medicine, University of Utah, Salt Lake City, UT.
Mark J CodyProgram in Molecular Medicine, University of Utah, Salt Lake City, UT.
Sharon C MorleyDivision of Infectious Diseases, Department of Pediatrics and.
Srikanth NagallaDivision of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Andrew S WeyrichProgram in Molecular Medicine, University of Utah, Salt Lake City, UT.
Jesse W RowleyProgram in Molecular Medicine, University of Utah, Salt Lake City, UT.
Ryan M O'ConnellDivision of Microbiology and Immunology, Department of Pathology, and.
Matthew T RondinaProgram in Molecular Medicine, University of Utah, Salt Lake City, UT.
Robert A CampbellProgram in Molecular Medicine, University of Utah, Salt Lake City, UT.
Paul F BrayProgram in Molecular Medicine, University of Utah, Salt Lake City, UT.
University of Utah · USThe University of Texas Southwestern Medical Center · USThomas Jefferson University · USWashington University in St. Louis · US

Funding

Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
Translational Control of Megakaryocyte and Platelet Gene Expression in DiseaseR35HL145237 · NHLBI · UNIVERSITY OF UTAH · PI WEYRICH, ANDREW S · 2019 to 2025
$4.7M
In vivo studies of megakaryocyte microRNAs regulating platelet number and integrin activationR01HL141424 · NHLBI · UNIVERSITY OF UTAH · PI BRAY, PAUL F. · 2018 to 2021
$2.5M
Investigating the transfer of miRNAs by exosomes during inflammationR01AI123106 · NIAID · UNIVERSITY OF UTAH · PI O'CONNELL, RYAN M · 2017 to 2021
$2.0M
Translational Control of Megakaryocyte and Platelet Function in SepsisR01HL142804 · NHLBI · UNIVERSITY OF UTAH · PI RONDINA, MATTHEW THOMAS · 2018 to 2021
$1.9M
Interferon-Induced Transmembrane Protein 3 (IFITM3) Regulates Thrombosis During Inflammation in AgingK01AG059892 · NIA · UNIVERSITY OF UTAH · PI CAMPBELL, ROBERT A · 2019 to 2022
$400k
Platelet Reprogramming During InflammationI01CX001696 · VA · VA SALT LAKE CITY HEALTHCARE SYSTEM · PI Matthew Thomas Rondina · 2018 to 2026
–
CSRD VA I01 CX001696NCATS NIH HHS UL1 TR002538NHLBI NIH HHS R01 HL141424NHLBI NIH HHS R35 HL145237NIAID NIH HHS R01 AI123106NIA NIH HHS K01 AG059892
6 · The paper itself

Abstract

There is heritability to interindividual variation in platelet count, and better understanding of the regulating genetic factors may provide insights for thrombopoiesis. MicroRNAs (miRs) regulate gene expression in health and disease, and megakaryocytes (MKs) deficient in miRs have lower platelet counts, but information about the role of miRs in normal human MK and platelet production is limited. Using genome-wide miR profiling, we observed strong correlations among human bone marrow MKs, platelets, and differentiating cord blood-derived MK cultures, and identified MK miR-125a-5p as associated with human platelet number but not leukocyte or hemoglobin levels. Overexpression and knockdown studies showed that miR-125a-5p positively regulated human MK proplatelet (PP) formation in vitro. Inhibition of miR-125a-5p in vivo lowered murine platelet counts. Analyses of MK and platelet transcriptomes identified LCP1 as a miR-125a-5p target. LCP1 encodes the actin-bundling protein, L-plastin, not previously studied in MKs. We show that miR-125a-5p directly targets and reduces expression of MK L-plastin. Overexpression and knockdown studies show that L-plastin promotes MK progenitor migration, but negatively correlates with human platelet count and inhibits MK PP formation (PPF). This work provides the first evidence for the actin-bundling protein, L-plastin, as a regulator of human MK PPF via inhibition of the late-stage MK invagination system, podosome and PPF, and PP branching. We also provide resources of primary and differentiating MK transcriptomes and miRs associated with platelet counts. miR-125a-5p and L-plastin may be relevant targets for increasing in vitro platelet manufacturing and for managing quantitative platelet disorders.

Indexed as

Gene Expression Regulation, DevelopmentalActinsBiomarkersBlood PlateletsGene Knockdown TechniquesHumansMegakaryocytesMembrane GlycoproteinsMicrofilament ProteinsMicroRNAsRNA InterferenceThrombopoiesisActinsBiomarkersMembrane GlycoproteinsMicrofilament ProteinsMicroRNAsMIRN125 microRNA, humanplastin

Identifiers

PMID32844999
PMCPMC7544541
OpenAlexW3041071831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.